Latency Period

The latency period is the interval between exposure to a harmful product or substance and the manifestation of a diagnosable injury or disease, which in mass tort litigation involving chronic disease — asbestos-related mesothelioma, certain cancers linked to chemical or pharmaceutical exposure, and similar disease processes — can extend anywhere from several years to several decades. Long latency periods create distinctive litigation and financing dynamics not present in acute-injury torts: claimants may not know they have a viable claim until long after exposure and after evidence, witnesses, and corporate records relevant to establishing exposure and causation have degraded or disappeared. Latency also interacts directly with statute of limitations analysis, since most jurisdictions apply a discovery rule that tolls the limitations period until the plaintiff knew or reasonably should have known of the injury and its connection to the defendant's conduct — a rule that becomes essential to claim viability precisely because latency can otherwise place claim accrual decades after the underlying exposure. Mass torts with long latency periods also tend to generate rolling waves of new claims over extended periods, as successive cohorts of exposed individuals are diagnosed years or decades apart.

Latency period length is a primary determinant of a mass tort docket's total duration and claim volume trajectory, and it directly shapes how a funder structures deployment horizon and reserve assumptions. A docket with a long latency profile requires funders to underwrite not just the currently filed claim population but the reasonably foreseeable future claim stream.

That forward-looking analysis is precisely what drives 524(g) trust sizing and future claimant representation in bankruptcy contexts, making latency modeling a first-order input for any long-duration mass tort financing commitment.